Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note released on Monday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 18.3 %

BTX stock opened at $0.26 on Monday. The company has a market cap of $15.52 million, a price-to-earnings ratio of -0.12 and a beta of 4.61. The business has a fifty day simple moving average of $0.35 and a 200-day simple moving average of $0.94. Brooklyn ImmunoTherapeutics has a 52 week low of $0.17 and a 52 week high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.